TrialBMC cancer2013

An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].

Stephen Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.